|
[1]Manns MP, McHutchison IG, Gordon SC, et al.Peginterferon alfa-2bpIus ribavirin for initial treatment of chronic hepatitis C:a randomized trial[J].Lancet, 2001, 358∶958-965.
|
|
[2]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon alfa-2a plusribavirin for chronic hepatitis C virus infection[J].N Engl J Med, 2002, 347∶975-982.
|
|
[3] Hadziyannis SJ, Cheinquer H, Morgan T, et al.Peginterferon alfa-2a (40kD) in combination with ribavirin:efficacy and safety results from aphaseⅢ.randomized, double-blind multi-center study examining ef-fect of duration of treatment and ribavirin dose[J].J Hepal, 2002, 36 (suppl 1) ∶3.
|
|
[4] Davis GL.Monitoring of viral levels during therapy of hepatitis C[J].Hepatology, 2002, 36∶s145-151.
|
|
[5] National Institutes of Health Consensus Development Conference state-ment:management of hepatitis C∶2002[J].Hepatology, 2002, 36∶s3-20.
|
|
[6]Russo MW, Fried MW.Side effects of therapy for chronic hepatitis C[J].Hepatology, 2003, 124∶1711-1719.
|
|
[7] Shiffman ML.Retreatment of patients with chronic hepatitis C[J].Hepa-tology, 2002, 26 (suppl 1) ∶s128-134.
|
|
[8]Cheng SJ, Bonis PAL, Lau J, et al.Interferon and ribavirin for patientswith chronic hepatitis C who did not respond to previous interferon thera-py:a metaanalysis of controlled and uncontrolled trial[J].Hepatology, 2001, 33∶231-240.
|
|
[9]Fontana RJ, Walsh J, Moyer CM, et al.High dose interferonα-2b andribavirin in patients previously treated with interferon:results of aprospective, randomized, controlled trial[J].J Clin Gastroenterol, 2002, 34∶177-178.
|
|
[10]Shiffman ML.Retreatment of HCV nonresponders with peginterferon andribavirin:results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis trial[abstract][J].Hepatology, 2002, 36∶295A.
|
|
[11]Selm K, Hyun C, Jensen J, et al.Histological improvement in patientswith pegylated interferon alpha-2b plus ribavirin who were previouslynonresponders to Rebetron[abstract][J].Gastroenterology, 2003, 124 (suppl 1) ∶217A.
|
|
[12]Alric L, Duffaut M, Selves J, et al.Maintenance therapy with gradualreduction of theinterferon dose over one year improves histological re-sponse in patients with chronic hepatitis C with biochemical response:re-sults of a randomized trial[J].J Hepatol, 2001, 35∶272-278.
|
|
[13] Yoshida H, Shiratori Y, Moriyama M, et al.Interferon therapy reducesthe risk for hepatocellular carcinoma:national surveillance program of cir-rhosis and noncirrhosis patients with chronic hepatitis C in Japan.IHZTStudy Group[J].Ann Intern Med, 1999, 131∶174-181.
|
|
[14]Fontana RJ.Nonresponders to hepatitis C virus antiviral therapy:pegy-lated interferon and beyond[J].Gastroenterol Clin N Am, 2004, 33∶527-547.
|
|
[15]Gross JB.Non-responders to previous treatment for hepatitis C[J].Minerva Gastroenterol Dietol, 2005, 51∶47-54.
|
PDF下载 ( 146 KB)
本文二维码
下载:
